Oncol Res Treat. 2018;41(12):755-761. doi: 10.1159/000492344. Epub 2018 Nov 13.
A high neutrophil to lymphocyte ratio (NLR) has been associated with adverse outcomes in non-small cell lung cancer (NSCLC). However, information on epidermal growth factor receptor (EGFR)-mutant advanced NSCLC is scarce, and most of the studies published have been conducted in Asian populations. We aimed to assess the influence of pretreatment NLR on progression-free survival (PFS) and overall survival (OS) in Western European patients treated with EGFR tyrosine kinase inhibitors (TKIs).
A retrospective evaluation of 41 patients with EGFR-mutant advanced NSCLC treated with EGFR TKIs between June 2010 and May 2016 was carried out. The association between several prognostic factors including pretreatment NLR and survival was analyzed.
Median PFS and OS were 10.58 and 20.84 months, respectively. OS for patients with a high NLR was 7.4 months, compared to 24.6 months for patients with a low NLR (p = 0.0122). In multivariate analysis, poor performance status (ECOG PS ≥ 2) and presence of ≥ 3 metastatic locations were identified as significant independent prognostic factors for worse PFS. For OS, unfavorable prognostic factors were a high NLR and central nervous system metastasis at diagnosis.
Pretreatment NLR is an independent prognostic factor for OS in Western European patients with EGFR-mutant NSCLC treated with EGFR TKIs.
高中性粒细胞与淋巴细胞比值（NLR）与非小细胞肺癌（NSCLC）的不良预后相关。然而，关于表皮生长因子受体（EGFR）突变型晚期 NSCLC 的信息很少，并且发表的大多数研究都是在亚洲人群中进行的。我们旨在评估 EGFR 酪氨酸激酶抑制剂（TKI）治疗的西方欧洲患者治疗前 NLR 对无进展生存期（PFS）和总生存期（OS）的影响。
对 2010 年 6 月至 2016 年 5 月接受 EGFR TKI 治疗的 41 例 EGFR 突变型晚期 NSCLC 患者进行了回顾性评估。分析了包括治疗前 NLR 在内的几种预后因素与生存之间的关系。
中位 PFS 和 OS 分别为 10.58 和 20.84 个月。高 NLR 患者的 OS 为 7.4 个月，而 NLR 低的患者为 24.6 个月（p = 0.0122）。多变量分析表明，较差的表现状态（ECOG PS ≥ 2）和存在≥3 个转移部位是 PFS 较差的独立显著预后因素。对于 OS，不利的预后因素是高 NLR 和诊断时中枢神经系统转移。
在接受 EGFR TKI 治疗的 EGFR 突变型西方欧洲 NSCLC 患者中，治疗前 NLR 是 OS 的独立预后因素。
